The abstract is read at the publisher; the summary is JClub's.
Dual augmentation of GRN and STMN2 in TDP-43 A315T transgenic mice significantly extended survival, preserved motor performance, and maintained neuromuscular integrity.
- Why it matters: ALS involves TDP-43 proteinopathy that disrupts axons and CNS homeostasis, and current therapies are limited against these linked pathologies.
- What they did: The study used a dual-gene therapeutic strategy delivering GRN and STMN2, testing effects in TDP-43 A315T transgenic mice and in human iPSC-derived motor neurons.
- The result: In mice, the combined treatment delayed disease progression, and in iPSC-derived motor neurons it promoted axonal regeneration after injury while coordinating neuronal, microglial lysosomal, and astrocyte support programs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.